The Federal Circuit’s decision in International Medical Devices, Inc. v. Cornell, Case No. 25-1580 -1605 (Fed. Cir. Apr. 17, 2026), provides an important reminder that trade secret law cannot be used to reclaim ideas already placed into the public domain through patents.
The dispute arose out of the highly specialized and somewhat unusual market for cosmetic penile implants. Plaintiffs International Medical Devices (“IMD”) and Dr. James Elist developed and marketed the Penuma® implant, which at the time was the only commercially available cosmetic penile implant.
After a physician training session attended by Dr. Robert Cornell, the relationship between the parties deteriorated into litigation involving trade secrets, inventorship, breach of contract, counterfeiting, and patent invalidity.
A California jury initially returned a sweeping verdict for the plaintiffs. Following a bench trial, the district court awarded more than $5.7 million in reasonable royalty damages, doubled that amount in exemplary damages, imposed a five-year injunction, and added $1 million in statutory trademark-counterfeiting damages.
The Federal Circuit reversed most of the judgment.
The opinion is significant because it sharply reinforces the boundary between patent law and trade secret law. Judge Dyk’s opinion repeatedly emphasized a straightforward principle: information disclosed in patents cannot later be protected as trade secrets merely because no one commercialized the disclosed concepts.
The Court’s “Generally Known” Analysis
The central issue involved four alleged trade secrets:
- Internal pockets or voids within the implant to improve softness and elasticity;
- Mesh tabs near the implant tip to promote tissue ingrowth;
- Use of absorbable sutures with the mesh tabs; and
- A surgical instrument and supply list.
Under California’s Uniform Trade Secrets Act, information qualifies as a trade secret only if it derives independent economic value from not being generally known and is subject to reasonable secrecy measures.
The Federal Circuit concluded that the first three alleged trade secrets had already been publicly disclosed in prior patents. The court relied heavily on longstanding precedent holding that information disclosed in patents is, by definition, publicly available and cannot later be treated as secret.
The court quoted its earlier decisions in Ultimax Cement Mfg. Corp. v. CTS Cement Mfg. Corp. and Atlantic Research Marketing Systems, Inc. v. Troy for the proposition that “[a] trade secret is secret. A patent is not.”
That portion of the opinion may not surprise trade secret practitioners. What makes the decision particularly interesting is how aggressively the court applied the “generally known” concept across adjacent technical fields.
“Same Problem, Same Solution”
The most consequential part of the opinion may be the court’s articulation of a broader principle limiting trade secret protection:
“No protectable trade secret results from translating a generally known concept from one environment to another environment where both environments present the same problem that is solved by the same solution.”
That language could have implications well beyond medical devices.
The plaintiffs attempted to distinguish prior art relating to therapeutic penile implants from their cosmetic implant technology. The court rejected the distinction because the underlying engineering problem, namely how to soften silicone implants, was materially the same.
Charles Gideon Korrell notes that this portion of the opinion reads almost like an obviousness analysis imported into trade secret doctrine. The Federal Circuit repeatedly emphasized that self-evident adaptations of known concepts cannot become trade secrets merely because they are applied in a neighboring field.
The court cited several analogous cases involving jet skis, bread-making processes, and wholesale-retail pricing structures to reinforce the point that trade secret law does not protect obvious translations of generally known concepts into adjacent applications.
That reasoning could become especially important in software and AI disputes, where companies often argue that adapting known architectures or workflows to new domains creates protectable confidential know-how.
The Instrument List Failed for a Different Reason
The fourth alleged trade secret, the Penuma® instrument and supply list, failed for a different reason.
Even assuming the list itself had value, the court concluded that plaintiffs failed to preserve secrecy because the list had been emailed to third parties without adequate confidentiality protections.
The opinion underscores a recurring problem in trade secret litigation: companies frequently assume that ordinary business communications are inherently confidential when, in reality, courts expect affirmative evidence of secrecy protections.
Here, the court found it significant that:
- the emails did not specifically designate the attachment as confidential;
- the NDA did not expressly identify the list as confidential information; and
- the list was shared with third parties without evidence of confidentiality obligations.
Charles Gideon Korrell believes this section of the opinion provides a practical warning for companies that rely heavily on NDAs but fail to operationalize confidentiality procedures in day-to-day communications. Courts increasingly expect concrete evidence showing that the company consistently treated the information as secret.
Breach of Contract Claim Collapsed Alongside the Trade Secrets
The breach of contract claim also failed because the NDA only protected confidential information, and plaintiffs identified no confidential information beyond the four alleged trade secrets. Once the court concluded the information was generally known or improperly protected, the contract claim necessarily fell apart as well.
This aspect of the opinion highlights a drafting issue that appears frequently in technology agreements. Many NDAs define confidential information using carveouts for information that becomes publicly known or independently developed. If the allegedly confidential information overlaps with prior patent disclosures or public technical literature, those carveouts can become dispositive.
Counterfeiting Claim Survived
The plaintiffs did preserve one substantial victory.
The Federal Circuit affirmed the counterfeiting verdict based on Dr. Cornell’s unauthorized use of the Penuma® mark to suggest he was an authorized Penuma® surgeon.
Defendants argued that the trademark registration covered goods rather than services. The court rejected that argument, explaining that the jury instructions properly required a finding that defendants used the mark in connection with the same goods covered by the registration.
The court also agreed there was sufficient evidence that defendants effectively offered the Penuma® implant itself for sale through their advertising.
As a result, the $1 million statutory damages award for counterfeiting survived intact.
Inventorship Theory Also Failed
The inventorship claim failed for essentially the same reason as the trade secret claims.
Plaintiffs argued that Dr. Elist should have been named as an inventor on two patents filed by defendants because he allegedly contributed the ideas involving internal pockets, mesh tabs, and absorbable sutures.
But the Federal Circuit held that contributions consisting only of generally known concepts cannot support inventorship.
The court further emphasized that the patent examiner ultimately allowed the claims only after applicants added limitations involving measured hardness differences across portions of the implant, a feature that plaintiffs never showed Dr. Elist contributed.
Charles Gideon Korrell notes that this portion of the opinion is particularly important for collaborative development environments. Inventorship disputes often focus on broad conceptual contributions, but this decision reinforces that the legally relevant inquiry is whether the alleged inventor contributed to the ultimately claimed invention, not merely to background concepts or prior-art ideas.
Broader Implications
The opinion is likely to become a frequently cited decision at the intersection of patent law and trade secret law.
Several themes stand out:
- Patent disclosures can extinguish later trade secret claims, even if the disclosed concepts were never commercialized.
- Adapting known concepts to adjacent technical environments may not create protectable trade secrets.
- Companies must actively preserve secrecy through operational controls, not merely generalized NDA language.
- Inventorship claims require contribution to the ultimately patentable aspects of the claims, not merely contributions to known concepts.
For technology companies, the decision may influence how engineering organizations document confidential know-how and how they distinguish proprietary implementation details from concepts already disclosed in patents or academic literature.
Charles Gideon Korrell believes the decision also reflects increasing judicial skepticism toward attempts to use trade secret law as a fallback form of patent protection after information has effectively entered the public domain.